Key result
Recombinant factor VIIa in intracerebral hemorrhage is linked to ~7-fold higher rates of elevated troponin and MI.
Why the study?
Does recombinant factor VIIa increase myocardial injury in patients with intracerebral hemorrhage?
Cohort (n=130)
Does recombinant factor VIIa increase myocardial injury in patients with intracerebral hemorrhage?
Absolute Event Rate: 20% vs 3%
p-value: p=0.02
Recombinant factor VIIa treatment in patients with intracerebral hemorrhage is associated with a significantly increased risk of myocardial injury and infarction.
rFVIIa in ICH may increase MI risk; leaves open causality and should not yet change practice.
We report myocardial injury in 20 recombinant factor VIIa (rFVIIa) treated and 110 nontreated patients with intracerebral hemorrhage. Patients were treated or received standard medical management. All received EKG and cardiac enzyme testing. Elevated troponin occurred in 20% treated vs 3% nontreated (p = 0.02). Myocardial infarction occurred in 10% vs 1% (p = 0.01). We found a significant increase in myocardial injury in rFVIIa treated patients.
No takes yet. Share an insight, caveat, or question.
Sugg et al. (2006) conducted a cohort in intracerebral hemorrhage (n=130). recombinant factor VIIa (rFVIIa) vs. standard medical management (nontreated) was evaluated on Elevated troponin (p=0.02). Recombinant factor VIIa treatment in patients with intracerebral hemorrhage was associated with significantly higher rates of elevated troponin (20% vs 3%, p=0.02) and myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: